SCHEMBL24537019

SCHEMBL24537019

CN(C)C(=O)c1cc(CNC(=O)OC(C)(C)C)n(C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
KDM4A O75164 1/20 0.38
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 4/20 0.35
GFER P55789 3/20 0.35
CACNA1H O95180 1/20 0.35
CACNA1B Q00975 1/20 0.35
CACNA1C Q13936 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ATR Q13535 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
MAPK14 Q16539 1/20 0.34
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24537014 0.86 KDM4E (0.43) KDM4ELMNAKDM4APOLBMAPK1
SCHEMBL24535670 0.85 KDM4E (0.45) KDM4ELMNAKDM4APOLBMAPK1
SCHEMBL24535672 0.85 KDM4E (0.42) KDM4ELMNAKDM4APOLBMAPK1
SCHEMBL30707488 0.83 KDM4E (0.38) KDM4ELMNAKDM4APOLBMAPK1
SCHEMBL30706671 0.81 KDM4E (0.34) KDM4ELMNAKDM4AL3MBTL1GFER
SCHEMBL30706682 0.80 GFER (0.37) KDM4ELMNAKDM4AL3MBTL1GFER
SCHEMBL30706766 0.80 GFER (0.37) KDM4ELMNAKDM4APOLBL3MBTL1
SCHEMBL30707173 0.80 GFER (0.37) KDM4ELMNAKDM4APOLBL3MBTL1
SCHEMBL30706899 0.79 GFER (0.36) KDM4ELMNAKDM4AL3MBTL1GFER
SCHEMBL30707428 0.79 GFER (0.36) KDM4ELMNAKDM4AL3MBTL1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS KDM4E 2625/4885LMNA 4180/4885KDM4A 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.